Characteristics of new adult users of mepolizumab with asthma in the USA

Characteristics of new adult users of mepolizumab with asthma in the USA

Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for patients aged ≥12 years with an eosinophilic phenoty...

Full description

Saved in:
Bibliographic Details
Main Authors: Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/8/1/e001003.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopenrespres.bmj.com/content/8/1/e001003.full

Similar Items